INTRODUCTION: Exercise may represent an effective adjunct therapy to current medical management strategies for maintaining functional independence and improving quality of life in cancer patients with bone metastatic disease. However, it has yet to be determined if there are any sustained effects following the completion of an exercise program by patients with bone metastases. PURPOSE: The aim of this study is to determine whether a 3-month supervised resistance exercise program results in any sustained functional benefits in prostate and breast cancer patients with bone metastatic disease. METHODS: Twenty men and women with bone metastatic disease secondary to prostate or breast cancer completed a 3-month supervised resistance exercise program followed by a 6-month observation period. Outcomes were assessed at baseline, post-exercise, and 6-month follow-up. RESULTS: Fourteen participants completed the follow-up observation period. Significant improvements in physical function (4-6 %), physical activity levels (~160 min/week), lean mass (3-4 %), and quality of life (5-7 %) were observed at the completion of the exercise program. At the 6-month follow-up, significant improvements in ambulation (4 %), physical activity level (~105 min/week), whole body lean mass (2 %), and quality of life (13 %) remained. CONCLUSIONS: An appropriately designed and supervised 3-month resistance exercise program may lead to significant improvements in functional ability, physical activity level, lean mass, and quality of life that remain 6 months after completion of the program in cancer patients with bone metastases. Future trials involving larger sample sizes are required to expand these preliminary findings.
INTRODUCTION: Exercise may represent an effective adjunct therapy to current medical management strategies for maintaining functional independence and improving quality of life in cancerpatients with bone metastatic disease. However, it has yet to be determined if there are any sustained effects following the completion of an exercise program by patients with bone metastases. PURPOSE: The aim of this study is to determine whether a 3-month supervised resistance exercise program results in any sustained functional benefits in prostate and breast cancerpatients with bone metastatic disease. METHODS: Twenty men and women with bone metastatic disease secondary to prostate or breast cancer completed a 3-month supervised resistance exercise program followed by a 6-month observation period. Outcomes were assessed at baseline, post-exercise, and 6-month follow-up. RESULTS: Fourteen participants completed the follow-up observation period. Significant improvements in physical function (4-6 %), physical activity levels (~160 min/week), lean mass (3-4 %), and quality of life (5-7 %) were observed at the completion of the exercise program. At the 6-month follow-up, significant improvements in ambulation (4 %), physical activity level (~105 min/week), whole body lean mass (2 %), and quality of life (13 %) remained. CONCLUSIONS: An appropriately designed and supervised 3-month resistance exercise program may lead to significant improvements in functional ability, physical activity level, lean mass, and quality of life that remain 6 months after completion of the program in cancerpatients with bone metastases. Future trials involving larger sample sizes are required to expand these preliminary findings.
Authors: J Zabora; K BrintzenhofeSzoc; P Jacobsen; B Curbow; S Piantadosi; C Hooker; A Owens; L Derogatis Journal: Psychosomatics Date: 2001 May-Jun Impact factor: 2.386
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Eduardo Ferriolli; Richard J E Skipworth; Paul Hendry; Angela Scott; Jacob Stensteth; Max Dahele; Lucy Wall; Carolyn Greig; Marie Fallon; Florian Strasser; Tom Preston; Kenneth C H Fearon Journal: J Pain Symptom Manage Date: 2012-01-24 Impact factor: 3.612
Authors: G Hechmati; S Cure; A Gouépo; H Hoefeler; V Lorusso; D Lüftner; I Duran; C Garzon-Rodriguez; J Ashcroft; R Wei; P Ghelani; A Bahl Journal: J Med Econ Date: 2013-03-15 Impact factor: 2.448
Authors: Philip J Saylor; Andrew J Armstrong; Karim Fizazi; Stephen Freedland; Fred Saad; Matthew R Smith; Bertrand Tombal; Kenneth Pienta Journal: Eur Urol Date: 2012-11-23 Impact factor: 20.096
Authors: Maureen E Lynch; Daniel Brooks; Sunish Mohanan; Min Joon Lee; Praveen Polamraju; Kelsey Dent; Lawrence J Bonassar; Marjolein C H van der Meulen; Claudia Fischbach Journal: J Bone Miner Res Date: 2013-11 Impact factor: 6.741
Authors: Gregory T Levin; Kenneth M Greenwood; Favil Singh; Daphne Tsoi; Robert U Newton Journal: Integr Cancer Ther Date: 2015-08-14 Impact factor: 3.279
Authors: Nicolas H Hart; Robert U Newton; Nigel A Spry; Dennis R Taaffe; Suzanne K Chambers; Kynan T Feeney; David J Joseph; Andrew D Redfern; Tom Ferguson; Daniel A Galvão Journal: BMJ Open Date: 2017-05-30 Impact factor: 2.692
Authors: Michelle Nadler; Daryl Bainbridge; Jennifer Tomasone; Oren Cheifetz; Rosalyn A Juergens; Jonathan Sussman Journal: Support Care Cancer Date: 2017-03-03 Impact factor: 3.603
Authors: Catherine M Jankowski; Marcia G Ory; Daniela B Friedman; Andrea Dwyer; Sarah A Birken; Betsy Risendal Journal: J Cancer Surviv Date: 2014-08-08 Impact factor: 4.442